Premium
Glucocorticoids in the treatment of bullous diseases
Author(s) -
DeHoratius Danielle M.,
Sperber Brian R.,
Werth Victoria P.
Publication year - 2002
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1046/j.1529-8019.2002.01538.x
Subject(s) - medicine , dermatology , glucocorticoid , cortisone acetate , cortisone , treatment modality , disease , autoimmune disease , intensive care medicine , immunology , surgery
This article reviews recent advances in the treatment and management of bullous diseases with glucocorticoids. Since the 1950s, when oral cortisone acetate was introduced for the treatment of dermatologic disease, glucocorticoids have remained an important treatment modality. In particular, glucocorticoids are very effective for patients with autoimmune diseases because of their anti‐inflammatory and immunosuppressive properties. However, patients with these diseases are often treated with prolonged courses of glucocorticoids, and consequently are at risk for steroid‐induced side effects. In this article we present an in‐depth discussion of the indications for glucocorticoid treatment in autoimmune blistering diseases. In addition, we discuss how to recognize, treat, and prevent side effects that result from the use of glucocorticoids.